Icatibant Acetate Patent Expiration
Icatibant Acetate is Used for treating acute attacks of hereditary angioedema by antagonizing bradykinin receptor. It was first introduced by Takeda Pharmaceuticals Usa Inc
Icatibant Acetate Patents
Given below is the list of patents protecting Icatibant Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Firazyr | US5648333 | Peptides having bradykinin antagonist action |
Jul 15, 2014
(Expired) | Takeda Pharms Usa |
Icatibant Acetate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List